We report the case of a 46-year-old male who developed dermatomyositis and a sarcoid-like reaction in association with testicular relapse of multiple myeloma. The myositis progressed despite chemotherapy directed at the underlying malignant disorder and immunosuppressive treatment. There was, however, a dramatic and sustained response to high-dose chemotherapy and autologous peripheral blood stem cell transplantation which resulted in resolution of the myopathy and partial resolution of the sarcoid-like reaction. This case report highlights the potential of autologous stem cell transplantation as treatment for para-neoplastic disorders associated with haematological malignancies. Bone Marrow Transplantation (2001) 27, 1215-1217. Keywords: multiple myeloma; autologous PBSCT; dermatomyositis; sarcoidosis The presenting clinical features of multiple myeloma are protean and reflect the direct effects of clonal plasma cell proliferation (eg bone marrow failure), the activity of monoclonal antibody (eg amyloid deposition), or the consequence of a complex inter-relationship between the abnormal clone and the host bone marrow micro-environment (eg bone disease). The pathogenesis of the various 'paraneoplastic' disorders which occur in association with myeloma, such as axonal or demyelinating neuropathy, is less certain although antibodies with specificity for proteins expressed by affected tissues, amyloid deposition or changes in cytokine production patterns have all been proposed as potential mechanisms. The optimal treatment for this group of disorders has not been defined and their impact upon prognosis is not known. We report for the first time the effectiveness of high-dose chemotherapy and peripheral blood stem cell transplantation (PBSCT) as treatment for a para-neoplastic disorder associated with multiple myeloma. 
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Case report
A 46-year-old man presented with a 3 month history of general malaise and 2 week history of vomiting in March 1998. There was no significant past medical history. On examination he appeared unwell and short of breath at rest. He had a raised venous pressure, peripheral oedema and bilateral inspiratory crepitations on chest examination. FBC at presentation was: Hb 8.2 g/dl, white cell count 5.2 × 10 9 /l and platelets 163 ϫ 10 9 /l. Renal function tests confirmed acute renal failure with a creatinine of 844 umol/l (normal range 62-130) and urea 46.4 mmol/l (normal range 2.8-7.6). Corrected serum calcium was 3.43 mmol/l. Chest Xray showed changes consistent with pulmonary oedema. Serum electrophoresis confirmed an IgG lambda paraprotein of 70 g/l. No urinary Bence-Jones protein was detected. Skeletal survey revealed no lytic lesions. Bone marrow trephine was diffusely fibrotic with deposition of collagen (grade 4) and heavy infiltration by neoplastic plasma cells (CD138 positive, lambda light chain restriction). Most plasma cells had the features of plasmblasts. Renal biopsy showed a cast nephropathy.
The diagnosis was of IgG lambda myeloma complicated by hypercalcaemia and acute renal failure. He was treated initially with an infusion of sodium pamidronate to correct the hypercalcaemia, and serial plasma exchange and haemodialysis over the next 8 days. He also received three pulses in quick succession of dexamethasone 40 mg daily for 4 days. His renal function improved rapidly and he required no further dialysis. He subsequently received five courses of VAD chemotherapy (vincristine 0.4 mg daily intravenously over 4 days (total dose 1.6 mg), adriamycin 9 mg/m 2 intravenously over 4 days (total dose 36 mg/m 2 ) and dexamethasone orally 40 mg once daily for 4 days), completing therapy in September 1998. After five courses of therapy he entered complete remission with no excess of plasma cells detectable on bone marrow aspirate and no detectable paraprotein. In November 1998 he underwent a successful peripheral blood stem cell harvest following cyclophosphamide (1.5 g/m 2 ) and G-CSF priming, with a view to proceeding to high-dose melphalan and PBSCT.
In January 1999, when admitted for PBSCT, he described a 6-week history of progressive weakness of both the upper and lower limbs associated with severe myalgia.
He also reported the development of a rash over his face and the dorsal aspect of his hands. On examination he had a bilateral symmetric violaceous rash over his knuckles and over his cheeks and peri-orbital region. There was bilateral symmetrical MRC grade 4/5 weakness of proximal upper and lower limb muscle groups without wasting or fasciculation. There was no other focal neurological deficit. An incidental finding was of a hard irregular enlargement of the left testis.
A bone marrow aspirate showed no excess of plasma cells and serum electrophoresis revealed a very faint, but non-quantifiable IgG lambda paraprotein. He underwent a left orchidectomy and histology of the testicular mass showed a plasmacytoma with the same monoclonal light chain restriction as at diagnosis.
Serum creatinine kinase levels were consistently normal. A general auto-antibody screen (anti-thyroglobulin, -thyroid microsomal, -gastric parietal cell, -smooth muscle, -mitochondrial and -DNA) was negative. A screen of antibodies to extractable nuclear antigen (anti-Ro/SSA, -La/SSB, -Sm, -RNP, -Jo-1 and -Sc170) was also negative. Electromyelograph studies of the right iliopsoas and tibialis anterior confirmed a moderate proximal myopathy with polyphasic stable units. A muscle biopsy from the vastus lateralis showed an excess of small atrophic, angulated fibres scattered throughout the biopsy and in some areas the distribution was perifasicular. Fibre typing showed type I predominance with some areas of grouping of type I and type II fibres. There was no significant inflammatory infiltration and the blood vessels appeared normal. Oxidative stains were normal. No inclusions or vacuoles were observed in the muscle fibres. Stains for glycogen, lipid, phosphorylase, acid phosphatase and adenylate deaminase were non-contributory.
A serum amyloid protein scan was performed, which was negative and an ECG and echocardiogram showed no evidence of a restrictive cardiomyopathy.
CXR at this stage showed a small right-sided pleural effusion and bilateral hilar lymphadenopathy, neither of which had been present at diagnosis. CT scan of chest, abdomen and pelvis demonstrated no evidence of lymphadenopathy elsewhere. Pleural fluid cytology was unremarkable. In order to identify the cause of the hilar lymphadenopathy, a mediastinoscopy and lymph node biopsy were performed. Lymph node histology showed complete effacement of the normal lymph node architecture by non-caseating granulomata. No acid alkali-fast bacilli were identified. Serum angiotensin converting enzyme levels were consistently normal.
The diagnoses were of dermatomyositis (DM) and a sarcoid-like reaction (SLR) complicating testicular relapse of multiple myeloma. Over the next 8 weeks the symptoms of myalagia and muscle weakness became more pronounced. He received a further course of VAD chemotherapy which resulted in a minor, but only transient improvement in his symptoms. He was therefore commenced on prednisolone 1 mg/kg orally but his symptoms continued to progress such that he had difficulty climbing stairs or carrying any significant weight. He proceeded to melphalan 200 mg/m 2 given intravenously and nonmanipulated PBSCT, at which time his Karnofsky score was 60%. The post-transplant course was complicated by severe grade III mucositis and a single episode of febrile neutropenia, but was otherwise uneventful. Over the next 4-6 weeks his condition improved dramatically with complete resolution of both the rash and clinical evidence of myopathy. At 18 months post PBSCT he has a Karnofsky score of 100% and remains in remission from his myeloma, with no features of DM and significant (Ͼ50%) reduction in the degree of hilar lymphadenopathy.
Discussion
This is the first case report to highlight the durable remission of a myeloma-associated para-neoplastic disorder following autologous stem cell transplant (SCT). The precise role of autologous SCT in the treatment of the autoimmune inflammatory myopathies has yet to be determined, but this case study and another recent report 1 illustrate that it may be feasible in patients with disease refractory to conventional immunosuppression. It is also consistent with the reported efficacy of autologous SCT for other auto-immune diseases. 2 The mechanisms of disease response to autologous SCT are not known but may include the eradication of auto-reactive T cell clones or thymic re-education. This patient received a non-manipulated, T cell-replete PBSCT, suggesting that physical removal of auto-reactive T cells from the graft is not a pre-requisite for a response in this setting. It is currently uncertain whether T cell depletion confers any overall benefit in the context of auto-immune disease.
The diagnosis of DM in this case was made using the criteria of Bohan and Peter:
3 symmetrical proximal muscle weakness, specific muscle biopsy findings, elevation of muscle-derived serum enzymes, typical electromyographic findings and characteristic cutaneous lesions. The diagnosis of DM can be made using four of these five criteria, as in this case where the serum creatinine kinase was consistently normal. The absence of inflammation in the muscle biopsy does not exclude the diagnosis. 3 Although the finding of hilar lymphadenopathy and biopsy finding of noncaseating epithelioid granulomata indicate an SLR, this case did not fulfil the criteria for systemic sarcoidosis since there was no objective evidence of involvement of more than one organ system. The association between multiple myeloma and both DM and the SLR are suggested first, by the temporal relationship of their onset and second, by a parallel clinical course. The durable regression of the myositis and decrease in hilar lymphadenopathy following autologous SCT would be consistent with the significant immune suppression induced by this treatment and/or by reduction in the myeloma tumour load. An estimation of the degree of tumour reduction in this case is difficult since, at the time of transplant, the testicular mass had been removed and paraprotein was present but at such a low level as to be non-quantifiable.
Although individual associations between lymphoproliferative disorders (LPDs) and both DM 4 or SLRs 5 have been reported previously, to our knowledge there are no descriptions of this triad. DM is associated with a five-to seven-fold increase in the incidence of malignancy 4 includ-ing in some, but not all studies, associations with LPDs. In the majority of these cases there is a close temporal association between the development of the LPD and DM. However, in contrast to other malignancies and this particular case report, few cases of DM are reported after the development of the LPD. To date, descriptions linking plasma cell dyscrasias and polymyositis or DM are rare with only a few reported cases (see Refs 6 and 7 and references therein). It is noteworthy that in three patients, including this one, the plasma cell dyscrasia was present at an extramedullary site (thyroid, gastric and testicular). 6, 7 SLRs have been described in patients with LPDs, either at the site of malignancy or at sites distinct from the reaction. 8 The reported frequency of non-caseating granulomas in patients with lymphoproliferative disorders is in the range of 7-14%. 8 Typically, these reactions are associated with local non-caseating granulomata and lack of symptoms, but their presence can cause diagnostic confusion or lead to inappropriate disease staging. Although a distinction is often made between an SLR and systemic sarcoidosis, it is possible that these two entities represent the clinical extremes of a common pathological process. Indeed, the existence of a 'sarcoid-lymphoma' syndrome has been proposed which is characterised by onset of lymphoma after the development of sarcoidosis. 5 In general, these features hold true for the reported associations between plasma cell dyscrasias and sarcoidosis. 8 The pathogenesis of DM or SLRs associated with malignancy is not known, but presumably involves a host immune response to tumour antigens. Granulomatous inflammation is driven by T helper 1 (Th1) cytokines such as IFN gamma and interleukin-2, a pattern consistent with the immuno-histochemical pattern of local cytokine expression demonstrable in the inflammatory myopathies. 9 The demonstration that idiotype-specific T cells in patients with myeloma frequently express Th1 cytokines 10 raises the possibility that a skewed immune response to myelomaspecific antigens leads to a perturbation of the cytokine milieu which, in turn, is capable of inducing a granulomatous reaction or inflammatory myopathy. Whether or not specific biological features of extramedullary disease influence the host immune response or increase the risk of certain paraneoplastic complications is not known.
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We conclude that autologous SCT may be an effective therapeutic option for patients with para-neoplastic disorders associated with multiple myeloma. Since other paraneoplastic phenomena, such as demyelinating or axonal neuropathies are relatively common complications of the plasma cell dyscrasias it should be feasible to study systematically whether dose escalation and autologous SCT confer any significant benefit in terms of outcome.
